Recombinant Human MYCBP protein

MYCBP (MYC-binding protein), also known as MYCBP2 or PAM (Primary microcephaly autosomal recessive protein 1), is a multifunctional E3 ubiquitin ligase implicated in regulating cellular processes such as neuronal development, cell proliferation, and tumorigenesis. It interacts directly with the MYC oncoprotein family (c-MYC, N-MYC, L-MYC), which are master transcription factors controlling cell cycle progression, metabolism, and apoptosis. MYCBP facilitates the ubiquitination and proteasomal degradation of MYC proteins, acting as a negative regulator to maintain MYC homeostasis. Dysregulation of this interaction is linked to MYC-driven cancers, where MYC overexpression promotes uncontrolled cell growth.

Recombinant MYCBP proteins are engineered using expression systems (e.g., E. coli, mammalian cells) to study its biochemical properties, structural motifs, and interaction networks. These proteins often include affinity tags (e.g., His, GST) for purification and detection. Key domains in MYCBP include the RING finger domain (critical for E3 ligase activity) and MYC-binding regions. Researchers use recombinant MYCBP to investigate its role in ubiquitination assays, MYC stability modulation, and pathways like Wnt/β-catenin or Notch signaling. Its involvement in neurodevelopmental disorders (e.g., microcephaly) and cancer metastasis has also spurred interest in therapeutic targeting. Structural studies of recombinant MYCBP have revealed binding interfaces with MYC and co-factors like USP28. which counteracts its degradative function. Current research explores small molecules to modulate MYCBP-MYC interactions, aiming to destabilize oncogenic MYC in tumors while sparing normal cells.